These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11864946)

  • 1. In vitro bactericidal activity of daptomycin against staphylococci.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
    Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients.
    Castagnola E; Amoroso L; Banov L; Faraci M; Loy A; Moscatelli A; Risso F; Barabino P; Ciucci A; Bandettini R
    J Chemother; 2014 Oct; 26(5):273-5. PubMed ID: 24070064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE; Moet GJ; Janechek MJ; Jones RN
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
    Leonard SN; Cheung CM; Rybak MJ
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2974-6. PubMed ID: 18519721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
    Rio-Marques L; Hartke A; Bizzini A
    Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of antibiotic susceptibilities and VISA-VRSA rates among MRSA strains isolated from hospitalized patients in intensive care units of hospitals in seven provinces of Turkey].
    Cesur S; Irmak H; Simşek H; Cöplü N; Kılıç H; Arslan U; Bayramoğlu G; Baysan BO; Gülay Z; Hoşoğlu S; Berktaş M; Gencer S; Demiröz AP; Esen B; Karabiber N; Aydın F; Yalçın AN
    Mikrobiyol Bul; 2012 Jul; 46(3):352-8. PubMed ID: 22951647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
    von Eiff C; Peters G
    J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.